Vigabatrin
Vigabatrin structure
|
Common Name | Vigabatrin | ||
|---|---|---|---|---|
| CAS Number | 68506-86-5 | Molecular Weight | 129.157 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 277.7±28.0 °C at 760 mmHg | |
| Molecular Formula | C6H11NO2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 121.7±24.0 °C | |
Use of VigabatrinVigabatrin(γ-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.IC50 value:Target: GABA transaminaseClinical studies have shown that vigabatrin is superior to placebo in decreasing the frequency of infantile spasms. In tuberous sclerosis, vigabatrin may be considered the first-line treatment for IS. The mode of action is increasing concentrations of the inhibitory neurotransmitter GABA in the brain.A significant increase in seizure threshold was observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of vigabatrin. Bilateral microinjection of vigabatrin (10 μg) into either the anterior or posterior SNr also increased seizure threshold, but less markedly than systemic treatment. |
| Name | Vigabatrin |
|---|---|
| Synonym | More Synonyms |
| Description | Vigabatrin(γ-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.IC50 value:Target: GABA transaminaseClinical studies have shown that vigabatrin is superior to placebo in decreasing the frequency of infantile spasms. In tuberous sclerosis, vigabatrin may be considered the first-line treatment for IS. The mode of action is increasing concentrations of the inhibitory neurotransmitter GABA in the brain.A significant increase in seizure threshold was observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of vigabatrin. Bilateral microinjection of vigabatrin (10 μg) into either the anterior or posterior SNr also increased seizure threshold, but less markedly than systemic treatment. |
|---|---|
| Related Catalog | |
| References |
[4]. Vigabatrin |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 277.7±28.0 °C at 760 mmHg |
| Molecular Formula | C6H11NO2 |
| Molecular Weight | 129.157 |
| Flash Point | 121.7±24.0 °C |
| Exact Mass | 129.078979 |
| PSA | 63.32000 |
| LogP | -0.10 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.483 |
| Storage condition | 2-8℃ |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
|---|---|
| RIDADR | NONH for all modes of transport |
| RTECS | MP7745000 |
|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Chem. Res. Toxicol. 23 , 171-83, (2010) Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental... |
|
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ... |
|
|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Nat. Chem. Biol. 3(5) , 268-273, (2007) The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain canc... |
| UNII:GR120KRT6K |
| vigabatrinum [INN_la] |
| (±)-γ-Vinyl-GABA |
| vigabatrine |
| Vigabatrin |
| vigabatrinum |
| 4-Aminohex-5-enoic acid |
| Sabril |
| vigabatrina |
| 4-Amino-5-hexenoic acid |
| 5-Hexenoic acid, 4-amino- |